BPG is committed to discovery and dissemination of knowledge
Featured Articles
1/22/2025 10:07:00 AM | Browse: 64 | Download: 82
Publication Name World Journal of Gastrointestinal Surgery
Manuscript ID 100257
Country China
Received
2024-08-11 13:30
Peer-Review Started
2024-08-11 13:30
To Make the First Decision
Return for Revision
2024-12-17 09:57
Revised
2024-12-18 13:46
Second Decision
2024-12-25 02:46
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief
2024-12-25 07:37
Articles in Press
2024-12-25 07:37
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2025-01-06 03:14
Publish the Manuscript Online
2025-01-22 09:26
ISSN 1948-9366 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Editorial
Article Title Programmed cell death receptor 1 inhibitor Pembrolizumab in the treatment of advanced gastric cancer
Manuscript Source Invited Manuscript
All Author List Xue-Mei Yi, Hong-Qiao Cai and Yan Jiao
Funding Agency and Grant Number
Funding Agency Grant Number
Jilin Provincial Natural Science Foundation No. YDZJ202401650ZYTS
Corresponding Author Yan Jiao, MD, PhD, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130021, Jilin Province, China. lagelangri1@126.com
Key Words Programmed cell death receptor 1 inhibitor; Pembrolizumab; Advanced gastric cancer; Chemotherapy; Trastuzumab
Core Tip In the past decade, programmed cell death receptor 1 (PD-1) inhibitors have shown significant anti-tumor effects and good safety in the treatment of various malignant tumors such as melanoma and non-small cell lung cancer. Multiple studies on advanced gastric cancer have shown that the combination therapy of PD-1 inhibitors can improve the efficacy. Pembrolizumab combined with chemotherapy or human epidermal growth factor receptor 2 targeting therapy have showed improved prognosis. In the future, it is important to explore the reasonable treatment sequence and dosage, to maximize the efficacy of combination therapy.
Publish Date 2025-01-22 09:26
Citation <p>Yi XM, Cai HQ, Jiao Y. Programmed cell death receptor 1 inhibitor Pembrolizumab in the treatment of advanced gastric cancer. <i>World J Gastrointest Surg</i> 2025; 17(2): 100257</p>
URL https://www.wjgnet.com/1948-9366/full/v17/i2/100257.htm
DOI https://dx.doi.org/10.4240/wjgs.v17.i2.100257
Full Article (PDF) WJGS-17-100257-with-cover.pdf
Manuscript File 100257_Auto_Edited_010624.docx
Answering Reviewers 100257-answering-reviewers.pdf
Audio Core Tip 100257-audio.mp3
Conflict-of-Interest Disclosure Form 100257-conflict-of-interest-statement.pdf
Copyright License Agreement 100257-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 100257-foundation-statement.pdf
Non-Native Speakers of English Editing Certificate 100257-non-native-speakers.pdf
Peer-review Report 100257-peer-reviews.pdf
Scientific Misconduct Check 100257-scientific-misconduct-check.png
Scientific Editor Work List 100257-scientific-editor-work-list.pdf
CrossCheck Report 100257-crosscheck-report.pdf